Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
IXHL Incannex Healthcare	$0.22 +7.8%	$0.49	$0.08 ▼ $3.55	$3.89M	7.67	10.29 million shs	26.68 million shs
KZIA Kazia Therapeutics	$3.58 +2.6%	$3.76	$2.86 ▼ $79.00	$3.61M	2.49	174,431 shs	12,132 shs
LSDI Lucy Scientific Discovery		$0.03	$0.44 ▼ $12.80	$907K	1.41	640,390 shs	314,500 shs
PALI Palisade Bio	$0.81 +6.7%	$0.72	$0.60 ▼ $5.38	$3.87M	1.46	515,875 shs	87,534 shs

10 Stocks Set to Soar in Spring 2025

Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Spring 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
IXHL Incannex Healthcare	-10.62%	-24.77%	-63.99%	-87.45%	-92.49%
KZIA Kazia Therapeutics	+1.75%	+2.65%	+1.45%	-20.68%	-75.71%
LSDI Lucy Scientific Discovery	0.00%	0.00%	0.00%	0.00%	-57.88%
PALI Palisade Bio	-0.59%	+11.23%	+9.81%	-19.79%	-85.34%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
IXHL Incannex Healthcare	0.4896 of 5 stars	0.0	2.0	0.0	0.0	3.0	1.7	0.0
KZIA Kazia Therapeutics	2.1227 of 5 stars	3.5	3.0	0.0	0.0	0.6	0.0	0.0
LSDI Lucy Scientific Discovery	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
PALI Palisade Bio	2.9482 of 5 stars	3.5	5.0	0.0	0.0	2.6	0.0	1.3

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
IXHL Incannex Healthcare	0.00	N/A	N/A	N/A
KZIA Kazia Therapeutics	3.00	Buy	$57.50	1,506.15% Upside
LSDI Lucy Scientific Discovery	0.00	N/A	N/A	N/A
PALI Palisade Bio	3.00	Buy	$12.00	1,386.99% Upside

Current Analyst Ratings Breakdown

Latest LSDI, IXHL, KZIA, and PALI Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target	Details
5/13/2025	PALI Palisade Bio	Brookline Capital Management Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$16.00 ➝ $16.00

(Data available from 5/23/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
IXHL Incannex Healthcare	$98K	39.67	N/A	N/A	$0.05 per share	4.35
KZIA Kazia Therapeutics	$2.31M	1.56	N/A	N/A	($1.97) per share	-1.82
LSDI Lucy Scientific Discovery	$16.73K	0.00	N/A	N/A	$2.86 per share	0.00
PALI Palisade Bio	$250K	15.48	N/A	N/A	$18.29 per share	0.04

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
IXHL Incannex Healthcare	-$18.46M	-$1.21	N/A	∞	N/A	N/A	-289.30%	-154.96%	N/A
KZIA Kazia Therapeutics	-$17.56M	N/A	0.00	∞	N/A	N/A	N/A	N/A	N/A
LSDI Lucy Scientific Discovery	-$8.99M	-$7.00	N/A	N/A	N/A	N/A	-294.74%	-137.65%	N/A
PALI Palisade Bio	-$12.30M	-$6.80	N/A	N/A	N/A	N/A	-148.51%	-115.16%	8/11/2025 (Estimated)

Latest LSDI, IXHL, KZIA, and PALI Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/15/2025	Q3 2025	IXHL Incannex Healthcare	-$0.46	-$0.24	+$0.22	-$0.20	$0.16 million	$0.10 million
5/12/2025	Q1 2025	PALI Palisade Bio	-$0.84	-$0.47	+$0.37	-$0.47	N/A	N/A
3/24/2025	Q4 2024	PALI Palisade Bio	-$2.39	-$0.69	+$1.70	-$0.69	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
IXHL Incannex Healthcare	N/A	N/A	N/A	N/A	N/A
KZIA Kazia Therapeutics	N/A	N/A	N/A	N/A	N/A
LSDI Lucy Scientific Discovery	N/A	N/A	N/A	N/A	N/A
PALI Palisade Bio	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
IXHL Incannex Healthcare	2.47	1.80	1.65
KZIA Kazia Therapeutics	N/A	0.24	0.24
LSDI Lucy Scientific Discovery	N/A	0.38	0.38
PALI Palisade Bio	N/A	3.31	3.31

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
IXHL Incannex Healthcare	0.43%
KZIA Kazia Therapeutics	30.89%
LSDI Lucy Scientific Discovery	72.61%
PALI Palisade Bio	11.79%

Insider Ownership

Company	Insider Ownership
IXHL Incannex Healthcare	26.53%
KZIA Kazia Therapeutics	1.00%
LSDI Lucy Scientific Discovery	N/A
PALI Palisade Bio	3.28%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
IXHL Incannex Healthcare	3	17.86 million	13.12 million	Not Optionable
KZIA Kazia Therapeutics	12	1.01 million	4.99 million	Optionable
LSDI Lucy Scientific Discovery	2	1.77 million	N/A	Not Optionable
PALI Palisade Bio	10	4.80 million	2.68 million	Not Optionable

LSDI, IXHL, KZIA, and PALI Headlines

Recent News About These Companies

Palisade Bio Q2 EPS Lifted by Brookline Capital Management

May 17, 2025 | americanbankingnews.com

Palisade Bio Presents Positive Preclinical Data Highlighting Potential of PALI-2108 as a Promising Colon-Specific PDE4 Inhibitor for the Treatment of Ulcerative Colitis and Other Inflammatory Bowel Diseases

May 6, 2025 | globenewswire.com

Palisade Bio's AI-Driven Approach to IBD Heterogeneity and Efficacy Selected for Presentation at the 3rd Annual Precision Medicine in Inflammatory Bowel Disease Summit

May 1, 2025 | globenewswire.com

Hyundai’s Next-Gen Hybrid System Offers 45% Boost In Fuel Efficiency

April 21, 2025 | msn.com

Palisade completes dosing in Phase 1b portion of Phase 1a/1n study of PALI-2108

April 9, 2025 | markets.businessinsider.com

Palisade Bio Completes Dosing in Phase 1a Portion of Ongoing Phase 1a/b Study of PALI-2108

April 9, 2025 | globenewswire.com

Maxim Group Sticks to Their Buy Rating for Palisade Bio (PALI)

March 27, 2025 | markets.businessinsider.com

Palisade Bio begins dosing subjects in last cohort of ulcerative colitis drug trial

March 17, 2025 | finance.yahoo.com

Palisade Bio commences dosing in first UC patient cohort in study of PALI-2108

March 14, 2025 | markets.businessinsider.com

Palisade Bio Reports Encouraging Preliminary Safety and Tolerability Data for PALI-2108 in Phase 1a/b Study for Ulcerative Colitis

March 14, 2025 | quiverquant.com

Palisade Bio Commences Dosing in First Ulcerative Colitis Patient Cohort in Ongoing Phase 1a/b Study of PALI-2108

March 14, 2025 | globenewswire.com

Palisade Bio Announces Two Abstracts Selected to be Showcased as Poster of Distinction and Poster Presentation at Leading GI Forum, Digestive Disease Week (DDW) 2025

March 12, 2025 | globenewswire.com

Palisade Bio (PALI) Upgraded to Buy: What Does It Mean for the Stock?

March 7, 2025 | zacks.com

Palisade Bio Participates in Virtual Investor “What This Means” Segment

March 4, 2025 | globenewswire.com

Palisade Bio receives cash proceeds from Canada’s SR&ED tax incentive program

February 20, 2025 | markets.businessinsider.com

Palisade Bio Secures CAD$1.39 Million in SR&ED Funding for PALI-2108 Development Efforts

February 20, 2025 | quiverquant.com

Palisade Bio, Inc. Announces Receipt of Cash Proceeds from Canada's SR&ED Tax Incentive Program for Reimbursement of Development Costs of PALI-2108 for Treatment of Ulcerative Colitis (UC)

February 20, 2025 | globenewswire.com

Palisade Bio, Inc. Participates in the Virtual Investor “Top 5 for ‘25” On-Demand Conference

February 19, 2025 | globenewswire.com

Palisade Bio presents preclinical data of PALI-2108

February 10, 2025 | markets.businessinsider.com

Palisade Bio Presents Positive Preclinical Data for PALI-2108 in Ulcerative Colitis at 2025 Crohn’s and Colitis Congress

February 10, 2025 | quiverquant.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

LSDI, IXHL, KZIA, and PALI Company Descriptions

Incannex Healthcare NASDAQ:IXHL

$0.22 +0.02 (+7.77%)

Closing price 04:00 PM Eastern

Extended Trading

$0.21 -0.01 (-3.08%)

As of 07:59 PM Eastern

Incannex Healthcare Inc., a clinical stage pharmaceutical development company, engages in the research, development, and sale of medicinal cannabinoid and psychedelic pharmaceutical products and therapies. It develops products for the treatment of obstructive sleep apnoea (OSA), traumatic brain injury (TBI) and concussion, lung inflammation (ARDS, COPD, asthma, bronchitis), rheumatoid arthritis, inflammatory bowel disease, anxiety disorders, addiction disorders, pain, and other indications. The company offers APIRx-1801, an ultrapure tetrahydrocannabinol; APIRx-1802, an ultrapure CBD; and APIRx-1803, an ultrapure cannabigerol. It also develops IHL-42X, which has completed Phase IIb clinical trial for obstructive sleep apnea; Psi-GAD that is in Phase IIa clinical trial for generalized anxiety disorder; MedChew Dronabinol, which has completed Phase Ia clinical trial for nausea and vomiting in chemotherapy; CanChew Plus that has completed Phase IIa clinical trial for irritable bowel syndrome; APIRx-1601, which has completed Phase IIa clinical trial for vitiligo; APIRx-1602 skin that has completed Phase IIa clinical trial for psoriasis; and APIRx-1603, which has completed Phase IIa clinical trial for atopic dermatitis. In addition, its product portfolio includes IHL-675A for inflammatory lung disease, IHL-675A for rheumatoid arthritis, IHL-675A for inflammatory bowel disease, and IHL-216A for traumatic brain injury and concussion, which have completed pre-clinical trials; and MedChew 1401 for pain and spasticity in multiple sclerosis, MedChew GB for post-herpatic neuralgia, MedChew-1502 for Parkinson's disease, MedChew-1503 for dementia, MedChew RL for restless legs syndrome, APIRx 1505 Flotex for chrohn's disease, CanChew RX and SuppoCan (Suppository) for inflammatory bowel disease, CheWell for addiction of cannabis, CanQuit for tobacco smoking cessation, CanQuit O for opioid addiction, APIRx-1701 for glaucoma, suppoCan gastro for IBD, and APIRx-1702 for dry eye syndrome that are in pre-clinical trials. Incannex Healthcare Inc. was incorporated in 2001 and is based in Sydney, Australia.

Kazia Therapeutics NASDAQ:KZIA

$3.58 +0.09 (+2.58%)

Closing price 03:59 PM Eastern

Extended Trading

$3.45 -0.13 (-3.63%)

As of 07:30 PM Eastern

Kazia Therapeutics Limited operates as an oncology-focused biotechnology company. The company's lead development candidate is Paxalisib, a small molecule, brain-penetrant inhibitor of the PI3K/AKT/mTOR pathway, which is developed as a potential therapy for glioblastoma. It also develops EVT801, a small-molecule selective inhibitor of vascular endothelial growth factor receptor 3. The company was formerly known as Novogen Limited and changed its name to Kazia Therapeutics Limited in November 2017. Kazia Therapeutics Limited was incorporated in 1994 and is based in Sydney, Australia.

Lucy Scientific Discovery NASDAQ:LSDI

Lucy Scientific Discovery Inc., an early stage psychotropics contract manufacturing company, engaged in the research, manufacturing, and commercialization of psychedelic products. The company offers biological raw materials, active pharmaceutical ingredients (APIs), and finished biopharmaceutical products. It also develops and produces highly controlled agricultural grow environments for plant manufacturing and replication applications. The company was formerly known as Hollyweed North Cannabis Inc. and changed its name to Lucy Scientific Discovery Inc. in May 2021. Lucy Scientific Discovery Inc. was incorporated in 2017 and is headquartered in Victoria, Canada.

Palisade Bio NASDAQ:PALI

$0.81 +0.05 (+6.68%)

Closing price 04:00 PM Eastern

Extended Trading

$0.80 -0.01 (-1.49%)

As of 07:45 PM Eastern

Palisade Bio, Inc., a clinical-stage biopharmaceutical company, focuses on focuses on developing therapeutics that protect the integrity of the intestinal barrier in the United States. The company's lead therapeutic candidate is PALI-2108, a prodrug PDE4 inhibitor, currently under pre-clinical development as a therapeutic for patients living with inflammatory bowel diseases, including ulcerative colitis and Crohn's disease (CD), as well as develops PALI-1908, an oral, selective PDE4 inhibitor prodrug that is locally bioactivated in the terminal ileum of CD patients, currently in the research stage. It has a research collaboration and license agreement with Giiant Pharma, Inc. for the development, manufacture, and commercialization of its compounds; a license agreement with the Regents of the University of California; a co-development and distribution agreement with Newsoara Biopharma Co., Ltd; and a transformative strategic collaboration with Strand Life Sciences for advancing precision medicine for ulcerative colitis therapy. The company is based in Carlsbad, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time